See we are on top of the pile lol. Would be nice to see today's percentage increase as a real reality one day. Wishfull thinking springs to mind but you never know as the product may be completely revolutionary. I guess a buy out may happen before the real value can be realised.
Very happy with the outcome yesterday. This may well be the best performing share in my portfolio. I've been a holder for seven years so I guess I could have made money else where lol. This share has been a roller coaster. Good luck to all holders.
The 3 year timescale is interesting as they're actually now planning and forecasting the future with more certainty. They have a number of commercial opportunities which should see revenues grow faster than they have. It's certainly been a bit of a slow burner but I suppose these pharma companies always are. The market seems to have liked what they've seen/heard though. I liked the part below from the RNS
The Company is engaged with a wide range of customers including large pharma and biotechs (including several of the top ten pharmaceutical companies), a number of diagnostics providers, several large bioprocessing and chromatography companies, and several EU, US and Asian academic and research institutes.
A key aspect of the business model is that a proportion of these custom Affimer projects and evaluations will lead to longer term commercial partnerships leading to payments for exclusivity, development milestones and longer term royalties on sales of Affimer containing products. The Company is negotiating a significant number of such commercial partnerships although these are taking longer than anticipated to complete.
Some interesting bits from the RNS, I'd be interested if anyone here went to the AGM
Following the Company's own progress in demonstrating the potential of Affimers as a therapeutic platform and the transformational therapeutic partnership that was established with Moderna Therapeutics in May 2015, Avacta successfully raised £21m net by way of a placing on 3 August 2015 with both existing and new institutional shareholders.
The proceeds will be used to accelerate the Group's in-house therapeutic programmes, focusing on oncology and blood clotting disorders; to support co-development partnerships; and to develop the therapeutic platform technology for key performance properties such as half-life extension, targeting and combination therapies. The primary strategic objective is to progress the first Affimer therapeutic into the clinic. This is expected to be achieved in approximately three years and this should be a significant value inflection point when it occurs.
Cotrel joins Avacta from Abcam, where he held the role of Commercial Operations Director. Cotrel will lead the Group's commercial strategy and business development activities, and will drive the commercialisation of the Affimer technology as both research reagents and biotherapeutics.
Avacta Group reports strong pre-clinical R&D progress for lead Affimer drug candidates against the PD-L1 immune checkpoint target, ahead of its annual general meeting today.
· Key collaboration initiated with Dr Ramzi Ajjan at the Leeds General Infirmary to carry out pre-clinical characterisation of Affimer drug candidates that modulate blood clotting in pre-clinical models.
· Affimer technology evaluations started with 13 large pharma and biotechs, including four of the ten largest pharma companies, and with several large diagnostics providers and numerous other commercial partners and academic institutes.
· Dr Mike Owen, ex- SVP and global Head of Research of Biopharmaceuticals R&D at GlaxoSmithKline, appointed as non-Executive Director and Chair of the Scientific Advisory Board. · Appointment today of Dr Philippe Cotrel, ex-Commercial Operations Director at Abcam, as Chief Commercial Officer (see separate press release). · Appointment of Mr Tony Gardiner as Chief Financial Officer.
· Successful £21m fund raising via a placing of ordinary shares to support an Affimer therapeutics development programme. · Avacta Animal Health trading at expected levels with further product launches planned for the second half of the financial year. · Half year revenue of £1.0m (£0.7m FY15) made up of £0.3m from Avacta Life Sciences and £0.7m from Avacta Animal Health. The Company expects to announce its Interim Results for the six months ended 31 January 2016 on Monday 25 April 2016.
Chief executive Dr Alastair Smith said: "I am very pleased with progress in the period. It is good to see the number and quality of customers and partners that are evaluating the Affimer technology growing steadily as potential licensing and commercial relationships arising from these evaluations are key to maximising medium- and long-term value. We will continue to focus our resources on supporting these evaluation projects with partners who can deliver significant commercial opportunities in the longer term. The additions to the Senior Leadership Team and to the Board are particularly important and I am delighted with the recent appointments. During the coming months, we will update the market in detail on the progress of our two principal in-house therapeutic development programmes that are focused on immune checkpoint inhibitors for cancer therapies and on modulators of blood clotting. We also expect to establish new facilities in Cambridge for the expanding therapeutic development activity under Dr Amrik Basran, and later in the year to move into larger premises in Wetherby to support the Affimer reagents development and manufacturing operations."
Separately, the group announced the appointment of Philippe Cotrel as Chief Commercial Officer of Avacta, with immediate effect. Cotrel joins Avacta from Abcam, where he held the role of Commercial Operations Di
I would agree with your thinking and I hope you're right. You would think the BOD have thought this through. We are over bought on the monthly chart which is a concern only news can keep us up at these levels and I believe past Q4 updates have been followed with positive news. Either way the co. looks like a great opportunity
I am not very good with predictions, but I would guess that the consolidation will be followed by a business update which should give enough support to the £1.27 price tag of each share, otherwise it may tank and I am sure that Alastair Smith is far to shrewd to allow that to happen
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.